泌尿器科領域感染症に対するritipenem acoxilの臨床的検討

書誌事項

タイトル別名
  • Clinical studies on ritipenem acoxil in urinary tract infections

この論文をさがす

抄録

We administered ritipenem acoxil (RIPM-AC), an oral penem-derived antibiotic, to patients with urinary tract infection (UTI) and evaluated its clinical efficacy and safety. RIPM-AC was administered after meals at a dose of 100-300 mg 3 times daily for 3 to 5 days to 12 patients with acute uncomplicated UTI, 19 patients with complicated UTI and 1 with acute bacterial prostatitis. The clinical efficacy of RIPM-AC was evaluated according to the Japanese UTI criteria. In 5 patients who fulfilled the UTI criteria for acute uncomplicated UTI, clinical efficacy was excellent in 4 and moderate in 1. In 12 patients who fulfilled the UTI criteria for complicated UTI, clinical efficacy was excellent in 6, moderate in 5 and poor in 1. As side effects, diarrhea was observed in 1 patient with complicated UTI. Laboratory examinations showed no abnormal values in any patient.

収録刊行物

参考文献 (3)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ